![](https://webarchive.library.unt.edu/eot2008/20090115035252im_/http://www.cancer.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/eot2008/20090115035252im_/http://www.cancer.gov/images/spacer.gif)
epratuzumab A recombinant, humanized monoclonal antibody directed against CD22, a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells. After binding to CD22, epratuzumab's predominant antitumor activity appears to be mediated through antibody-dependent cellular cytotoxicity (ADCC). Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
![](https://webarchive.library.unt.edu/eot2008/20090115035252im_/http://www.cancer.gov/images/spacer.gif)
Synonyms: | ![](https://webarchive.library.unt.edu/eot2008/20090115035252im_/http://www.cancer.gov/images/spacer.gif) | AMG 412 Humanized Anti-CD22 Monoclonal Antibody IgG1 LL2 monoclonal antibody LL2 | | ![](https://webarchive.library.unt.edu/eot2008/20090115035252im_/http://www.cancer.gov/images/spacer.gif) | US brand name: | ![](https://webarchive.library.unt.edu/eot2008/20090115035252im_/http://www.cancer.gov/images/spacer.gif) | LymphoCide | | ![](https://webarchive.library.unt.edu/eot2008/20090115035252im_/http://www.cancer.gov/images/spacer.gif) | Abbreviations: | ![](https://webarchive.library.unt.edu/eot2008/20090115035252im_/http://www.cancer.gov/images/spacer.gif) | hLL2 MOAB LL2 | | ![](https://webarchive.library.unt.edu/eot2008/20090115035252im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20090115035252im_/http://www.cancer.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090115035252im_/http://www.cancer.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090115035252im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20090115035252im_/http://www.cancer.gov/images/spacer.gif) |